Literature DB >> 7545148

Case study: corticosteroid treatment of language regression in pervasive developmental disorder.

G A Stefanatos1, W Grover, E Geller.   

Abstract

The authors describe a child whose language and behavior regressed at 22 months and in whom pervasive developmental disorder was later diagnosed. At 6 years, he displayed a profound receptive-expressive aphasia accompanied by behavioral disturbances characterized by hyperactivity, impaired social interactions, tantrums, gestural stereotypies, and echolalia. A single-photon emission computed tomography scan and steady-state auditory evoked potentials suggested bitemporal and left frontal pathophysiology. The overall profile resembled Landau-Kleffner syndrome, but no electroencephalographic disturbance was evident. Corticosteroid treatment resulted in amelioration of language abilities and behavior. These findings suggest that the factors underlying language regression in pervasive developmental disorder can, in special circumstances, be amenable to pharmacological treatment.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7545148     DOI: 10.1097/00004583-199508000-00022

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  17 in total

1.  Secretin and autism: a two-part clinical investigation.

Authors:  M G Chez; C P Buchanan; B T Bagan; M S Hammer; K S McCarthy; I Ovrutskaya; C V Nowinski; Z S Cohen
Journal:  J Autism Dev Disord       Date:  2000-04

2.  Treatment of seizure disorders and EEG abnormalities in children with autism spectrum disorders.

Authors:  R Tuchman
Journal:  J Autism Dev Disord       Date:  2000-10

Review 3.  Immune therapy in autism: historical experience and future directions with immunomodulatory therapy.

Authors:  Michael G Chez; Natalie Guido-Estrada
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 4.  Beyond the brain: A multi-system inflammatory subtype of autism spectrum disorder.

Authors:  Robyn P Thom; Christopher J Keary; Michelle L Palumbo; Caitlin T Ravichandran; Jennifer E Mullett; Eric P Hazen; Ann M Neumeyer; Christopher J McDougle
Journal:  Psychopharmacology (Berl)       Date:  2019-05-28       Impact factor: 4.530

Review 5.  Corticosteroids and Cognition: A Meta-Analysis.

Authors:  Catherine E Prado; Simon F Crowe
Journal:  Neuropsychol Rev       Date:  2019-05-26       Impact factor: 7.444

Review 6.  Immune Abnormalities in Autism Spectrum Disorder-Could They Hold Promise for Causative Treatment?

Authors:  Dominika Gładysz; Amanda Krzywdzińska; Kamil K Hozyasz
Journal:  Mol Neurobiol       Date:  2018-01-06       Impact factor: 5.590

Review 7.  Regression in autistic spectrum disorders.

Authors:  Gerry A Stefanatos
Journal:  Neuropsychol Rev       Date:  2008-10-28       Impact factor: 7.444

Review 8.  The role of epilepsy and epileptiform EEGs in autism spectrum disorders.

Authors:  Sarah J Spence; Mark T Schneider
Journal:  Pediatr Res       Date:  2009-06       Impact factor: 3.756

9.  Brain region-specific decrease in the activity and expression of protein kinase A in the frontal cortex of regressive autism.

Authors:  Lina Ji; Ved Chauhan; Michael J Flory; Abha Chauhan
Journal:  PLoS One       Date:  2011-08-31       Impact factor: 3.240

10.  Reduced activity of protein kinase C in the frontal cortex of subjects with regressive autism: relationship with developmental abnormalities.

Authors:  Lina Ji; Abha Chauhan; Ved Chauhan
Journal:  Int J Biol Sci       Date:  2012-08-30       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.